论文部分内容阅读
目的:治疗老年非小细胞肺癌(NSCLC)目前推荐第三代单药化疗,紫杉醇脂质体单药治疗老年(≥70岁)NSCLC的疗效及不良反应未见前瞻性研究报道,本研究旨在评价其治疗老年NSCLC的疗效及安全性。方法:26例经病理或细胞学确诊的老年NSCLC患者,有21例患者合并程度不等的各种并发症。采用紫杉醇脂质体135mg/m2,静脉滴注3h,d1,21天为1周期。结果:入组26例患者,均可评价疗效及不良反应。3例部分缓解,9例病情稳定,有效率11.5%,疾病控制率42.3%。中位生存期12.5个月。接受紫杉醇脂质体化疗4周期及以上患者的疾病控制率达66.7%,化疗不足4周期患者的疾病控制率为18.2%。ⅠB～Ⅲ期及Ⅳ期患者化疗后疾病控制率分别为38.5%和53.8%,中位生存期分别为13.8个月和10.0个月。主要不良反应有骨髓抑制,胃肠道反应及肝功能异常,多为Ⅰ～Ⅱ度反应。无化疗相关性死亡。结论:紫杉醇脂质体单药治疗老年(≥70岁)NSCLC毒性低,疗效较好,是老年肺癌单药化疗安全可靠的一种治疗选择。
PURPOSE: To treat elderly non-small cell lung cancer (NSCLC) currently recommended third-generation single-agent chemotherapy, paclitaxel liposomal monotherapy for the treatment of elderly (≥70 years) NSCLC efficacy and adverse reactions were not reported prospective studies, the purpose of this study Evaluate its efficacy and safety in the treatment of elderly NSCLC. METHODS: Twenty-six elderly patients with NSCLC diagnosed by pathology or cytology had various complications with varying degrees of consolidation in 21 patients. Paclitaxel liposomes 135mg / m2, intravenous infusion 3h, d1, 21 days for a cycle. Results: Into the group of 26 patients, can evaluate the efficacy and adverse reactions. 3 patients were partially relieved, 9 patients were stable, the effective rate was 11.5% and the disease control rate was 42.3%. The median survival was 12.5 months. Patients receiving paclitaxel at a dose of 4 cycles or more had a 66.7% disease control rate and a disease control rate of 18.2% in patients with less than 4 cycles of chemotherapy. The rates of disease control after chemotherapy in stage ⅠB-Ⅲ and stage Ⅳ were 38.5% and 53.8% respectively, and the median survival time was 13.8 months and 10.0 months respectively. The main adverse reactions are myelosuppression, gastrointestinal reactions and abnormal liver function, mostly Ⅰ ~ Ⅱ degree response. No chemotherapy-related death. CONCLUSION: Paclitaxel liposomes for the treatment of elderly patients (≥70 years) with low toxicity and good curative effect of NSCLC are safe and reliable single-agent chemotherapy for elderly patients with lung cancer.